Navrogen Granted Composition and Use Patent to Humoral Immuno-Oncology Factor Antagonist NAV-005 to Treat Cancer
CHEYNEY, PA, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies and humoral immunosuppressive factor antagonists to treat cancer, announced today …